Your browser is no longer supported. Please, upgrade your browser.
MYL Mylan N.V. daily Stock Chart
Mylan N.V.
IndexS&P 500 P/E40.86 EPS (ttm)0.65 Insider Own0.30% Shs Outstand513.64M Perf Week-0.93%
Market Cap13.72B Forward P/E5.68 EPS next Y4.70 Insider Trans-0.74% Shs Float510.38M Perf Month-8.65%
Income338.00M PEG8.01 EPS next Q0.81 Inst Own86.50% Short Float2.34% Perf Quarter-9.70%
Sales11.43B P/S1.20 EPS this Y-57.40% Inst Trans-0.14% Short Ratio2.19 Perf Half Y-19.08%
Book/sh23.63 P/B1.13 EPS next Y6.81% ROA1.00% Target Price36.31 Perf Year-34.53%
Cash/sh0.87 P/C30.80 EPS next 5Y5.10% ROE2.80% 52W Range26.00 - 42.50 Perf YTD-2.48%
Dividend- P/FCF6.57 EPS past 5Y-16.70% ROI3.50% 52W High-36.99% Beta1.47
Dividend %- Quick Ratio0.80 Sales past 5Y10.60% Gross Margin40.00% 52W Low3.00% ATR0.63
Employees35000 Current Ratio1.40 Sales Q/Q-4.90% Oper. Margin7.70% RSI (14)35.77 Volatility2.09% 2.29%
OptionableYes Debt/Eq1.14 EPS Q/Q-83.90% Profit Margin3.10% Rel Volume0.71 Prev Close26.72
ShortableYes LT Debt/Eq1.08 EarningsMay 28 AMC Payout0.00% Avg Volume5.45M Price26.78
Recom1.90 SMA20-2.59% SMA50-5.88% SMA200-17.86% Volume1,761,626 Change0.22%
Mar-20-19Initiated SunTrust Buy $35
Mar-07-19Resumed UBS Neutral $31
Mar-06-19Upgrade Morgan Stanley Equal-Weight → Overweight $35
Feb-27-19Downgrade Bernstein Outperform → Mkt Perform $33
Jan-23-19Downgrade UBS Buy → Neutral
Nov-15-18Upgrade Argus Hold → Buy
Nov-06-18Upgrade BofA/Merrill Neutral → Buy
Oct-09-18Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-05-18Downgrade Mizuho Buy → Neutral
Aug-24-18Upgrade Evercore ISI In-line → Outperform
Aug-13-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Mar-15-18Reiterated Mizuho Buy $45 → $51
Mar-06-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-25-18Reiterated Susquehanna Positive $47 → $55
Jan-04-18Reiterated Citigroup Buy $48 → $58
Jan-03-18Initiated Leerink Partners Mkt Perform $44
Dec-12-17Initiated Guggenheim Buy $59
Nov-07-17Reiterated RBC Capital Mkts Sector Perform $32 → $37
Oct-04-17Reiterated BTIG Research Buy $42 → $45
Apr-18-19 08:00AM  TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens to Treat Tuberculosis (TB) PR Newswire
Apr-16-19 02:04PM  Recordati to seek Canadian approval for kidney disease drug Reuters
11:41AM  Allergan Falls as Supreme Court Dismisses Restasis Litigation Zacks
Apr-15-19 09:46AM  U.S. Supreme Court rejects Allergan bid to use tribe to shield drug patents Reuters
Apr-14-19 12:15PM  Stocks That Fell to 3-Year Lows in the Week of April 12
Apr-11-19 10:04AM  Acorda to Gain From Inbrija Sales and Neurological Pipeline Zacks
Apr-03-19 11:00AM  Striving to Create Better Health for a Better World: Mylan's Global Social Responsibility 2018 Progress Report Now Available PR Newswire
Apr-01-19 12:27PM  Heres What Hedge Funds Think About Mylan N.V. (MYL) Insider Monkey
07:02AM  BMOs Got A Point About Teva Stock, But Are Investors Willing To Listen? InvestorPlace
Mar-28-19 09:30AM  Mylan (MYL) Up 8.6% Since Last Earnings Report: Can It Continue? Zacks
08:32AM  Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL) Zacks
Mar-22-19 01:36PM  Fed Up with Record of Earnings Misguidance, Investors Shun Mylan Bloomberg
08:44AM  Biogen stock downgraded to neutral from buy at UBS MarketWatch
Mar-20-19 10:43AM  Glaxo Presents Encouraging Data on Endometrial Cancer Drug Zacks
Mar-18-19 02:34PM  Mylan voluntarily recalls two lots of its levoleucovorin injection MarketWatch
12:48PM  Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate Matter PR Newswire
08:00AM  Mapi Pharma Receives Government of Israel Funding for the Establishment of a Finished Dosage Form Facility for the Manufacturing of GA Depot Pharmaceuticals GlobeNewswire
Mar-14-19 03:12PM  5 Undervalued Stocks to Invest In InvestorPlace
12:27PM  Investors Are Paying the Price as Drugmakers Flood Bond Market Bloomberg
11:01AM  Insys Plunges on Auditor's Concern About Insufficient Funds Zacks
Mar-13-19 01:13PM  SEC Closes Probe Into Mylan's Real-Estate Dealings with Former Director The Wall Street Journal
Mar-12-19 03:46PM  FDA approves generic valsartan amid drug shortage Reuters
Mar-08-19 11:39AM  Why Biggest Valuation Gap In 70 Years Is Buying Opportunity Investopedia
Mar-07-19 03:00PM  SBP, Mylan Present Keys to Hurricane Maria Survivor in Welcome Home Party -- Courtesy of $1M Pledge from the Mylan Charitable Foundation PR Newswire
02:14PM  Biotech shares continue to fall on FDA uncertainty CNBC
07:25AM  New Research: Key Drivers of Growth for Toll Brothers, Mylan N.V, Eldorado Resorts, Sinclair Broadcast Group, Eldorado Gold, and Pegasystems Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-06-19 08:59AM  US STOCKS-Wall St set for muted open due to lack of fresh catalysts Reuters
07:05AM  Here are the biggest analyst calls of the day: General Electric,Tripadvisor, VMware, Mylan, Teva CNBC
Mar-05-19 05:05PM  FDA's Scott Gottlieb Resigns What's Next For Biotech, Pharma? Investor's Business Daily
Mar-01-19 03:52PM  Mylan N.V. -- Moody's affirms Mylan's ratings; stable outlook Moody's
02:37PM  3 Life Sciences Stocks to Invest In InvestorPlace
06:34AM  Edited Transcript of MYL earnings conference call or presentation 26-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
Feb-28-19 10:01PM  Pfizer unit Meridian under civil investigation by U.S. Attorney Reuters
02:50PM  Richard S. Pzenas Pzena Investment Managements Return, AUM, and Holdings Insider Monkey
02:00PM  Mylan to Present at Raymond James 40th Annual Institutional Investors Conference PR Newswire
11:09AM  Mylan Stock May Fall Further After Hitting 52-Week Lows InvestorPlace
08:52AM  Implied Volatility Surging for Mylan (MYL) Stock Options Zacks
06:54AM  Mylan stock spirals after earnings miss and weak guidance MarketWatch
Feb-27-19 05:07PM  The Dow Finishes Lower Again Because Too Much Is Up in the Air -15.06%
04:33PM  Why Axon Enterprise, Mylan, and Weight Watchers International Slumped Today Motley Fool
04:28PM  Weight Watchers plunges, Best Buy and Campbell Soup jump Associated Press
04:04PM  Mylan's Disappointing Outlook Rattles Analysts, Investors Benzinga
03:38PM  US STOCKS-Wall St steadies after Lighthizer, Powell, Cohen testimonies Reuters
03:16PM  Tough Times Ahead for Mylan
01:30PM  US STOCKS-Wall St edges lower after Lighthizer comments on trade talks Reuters
12:48PM  Theravance (TBPH) Q4 Loss Narrows, Revenues Beat Estimates Zacks
12:08PM  Stocks making the biggest moves midday: Best Buy, IMAX, Campbell Soup, Mylan & more CNBC
11:59AM  US STOCKS-Wall St falls after Lighthizer's comments on trade talks Reuters
11:49AM  Mylan (MYL) Q4 Earnings & Revenues Miss Estimates, Stock Down Zacks
11:25AM  Why Mylan Shares Are Sinking Today Motley Fool
11:17AM  Mylan Drops Most in Three Years Despite Vow of Shift Bloomberg
10:21AM  Mylan Fails to Deliver as Many on Street Call for Change Bloomberg
09:58AM  US STOCKS-Wall St dips as Trump-Kim summit starts, India-Pakistan tensions flare Reuters
09:57AM  Mylan Falls on Fourth-Quarter Earnings and Guidance Miss
09:47AM  Mylan shares sink as bleak profit outlook sparks growth concerns Reuters
09:01AM  US STOCKS-Wall St set to open lower as Trump-Kim summit starts, India-Pakistan tensions flare Reuters
08:25AM  Stocks making the biggest moves premarket: Lowe's, Best Buy, Weight Watchers, Office Depot & more CNBC
08:15AM  What's Behind Mylan's Disappointing Q4 Earnings? Motley Fool
08:13AM  The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings Benzinga
08:08AM  Here are the biggest analyst calls of the day: Home Depot, Philip Morris, Weight Watchers CNBC
04:41AM  Mylan (MYL) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-26-19 09:35PM  Theravance Biopharma Inc (TBPH) Q4 2018 Earnings Conference Call Transcript Motley Fool
08:00PM  Revance Therapeutics Inc (RVNC) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:30PM  Mylan quarterly profit, 2019 forecast miss Wall Street estimates Reuters
06:08PM  Mylan misses, offers weak guidance CNBC Videos
05:51PM  Stocks making the biggest moves after hours: Weight Watchers, Papa John's, Mylan and more CNBC
05:30PM  Mylan Stock Plunges As Earnings Lag, Sales Meet; Guidance Mixed Investor's Business Daily
05:02PM  Mylan's fourth-quarter revenue falls 5 percent Reuters
05:01PM  Mylan stock drops 6% as earnings, forecast come in short of profit expectations MarketWatch
04:49PM  Mylan Reports Fourth Quarter and Full Year 2018 Results and Provides 2019 Guidance PR Newswire
03:00PM  Mylan N.V. to Host Earnings Call ACCESSWIRE
12:05PM  Mylan Earnings miss, Revenue beats In Q4
Feb-25-19 02:48PM  Mylan Expected to Earn $1.35 a Share
10:28AM  Momenta (MNTA) Q4 Loss Narrower Than Expected, Revenues Beat Zacks
Feb-24-19 01:40PM  Fed Chair Powell, big pharma head to the hill What to know in the week ahead Yahoo Finance
Feb-22-19 08:00AM  Mylan Launches Generic Suboxone® Sublingual Film to Treat Opioid Dependence PR Newswire
Feb-21-19 03:09PM  EpiPen Producer Nears Historically Bearish Trendline Schaeffer's Investment Research
02:59PM  6 Hot Stocks For Goldman Sachs New Investing Strategy InvestorPlace
10:30AM  Mapi Pharma to Host Key Opinion Leader Meeting on Long Acting Glatiramer Acetate (GA Depot) for Primary Progressive Multiple Sclerosis and New Treatments for MS GlobeNewswire
08:59AM  Biogen stock down 1.2% after downgrade by Stifel MarketWatch
Feb-20-19 03:09PM  Mylan (MYL) to Report Q4 Earnings: What's in the Offing? Zacks
Feb-19-19 09:50AM  U.S. top court rejects Maryland bid to revive drug price-gouging law Reuters
06:00AM  Teva expects sales injection from U.S. EpiPen market Reuters
03:42AM  Teva Pharm expects about 25 pct of EpiPen market by year end Reuters
Feb-15-19 04:35PM  Mylan Inc. -- Moody's announces completion of a periodic review of ratings of Mylan N.V. Moody's
10:29AM  Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates Zacks
Feb-14-19 10:02AM  Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise Zacks
Feb-12-19 11:01AM  Mylan launches Advair generic at one-third price Reuters
10:00AM  Mylan Launches Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), the First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder), at a List Price 70% Less than the Brand PR Newswire
Feb-11-19 10:24AM  Mylan to Release 2018 Fourth Quarter and Full Year Results and 2019 Guidance on Feb. 26, 2019 PR Newswire
10:17AM  Goldman Sachs pulls plug on 2-year-old, market-beating recommendation Yahoo Finance
Feb-08-19 05:13PM  Teva (TEVA) to Report Q4 Earnings: What's in the Cards? Zacks
09:53AM  Pfizer Japan recalls high blood pressure drug over cancer-causing impurity Reuters
Feb-07-19 04:11PM  Why Biogen's 'Battle-Tested' MS Drug Could Win Another Patent Dispute Investor's Business Daily
01:29PM  Biogen Stock Slips on a Setback in a Patent Dispute With Mylan
09:00AM  Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19 Zacks
Feb-03-19 09:01AM  A War on High Drug Prices Could Boost Biosimilars Motley Fool
Feb-01-19 05:58PM  Mylan's Generic Version of Advair Diskus Wins FDA Approval Zacks
Jan-31-19 07:23PM  J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study Zacks
04:06PM  6 Poorly Performing Stocks in Gurus' Portfolios
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gallagher Daniel Martin JrChief Legal OfficerApr 01Option Exercise0.008,515021,133Apr 03 06:00 PM
Campbell PaulSee RemarksMar 04Sale27.5011,533317,14324,137Mar 05 06:15 PM
BRESCH HEATHER MChief Executive OfficerMar 03Option Exercise0.0020,1420394,503Mar 05 06:06 PM
Gallagher Daniel Martin JrChief Legal OfficerMar 03Option Exercise0.008,218016,567Mar 05 06:09 PM
Mauro AnthonyChief Commercial OfficerMar 03Option Exercise0.005,534098,537Mar 05 06:11 PM
Malik RajivPresidentMar 03Option Exercise0.0012,3950275,388Mar 05 06:11 PM
Parks Kenneth ScottChief Financial OfficerMar 03Option Exercise0.003,984016,853Mar 05 06:13 PM
Campbell PaulSee RemarksMar 03Option Exercise0.002190599Mar 05 06:15 PM
Campbell PaulSee RemarksMar 03Option Exercise0.00830024,493Mar 05 06:15 PM
Campbell PaulSee RemarksMar 02Option Exercise0.001670437Mar 05 06:15 PM
Campbell PaulSee RemarksMar 02Option Exercise0.001,980024,540Mar 05 06:15 PM
Parks Kenneth ScottChief Financial OfficerMar 02Option Exercise0.006,103015,541Mar 05 06:13 PM
Malik RajivPresidentMar 02Option Exercise0.0014,6450269,457Mar 05 06:11 PM
Mauro AnthonyChief Commercial OfficerMar 02Option Exercise0.006,103095,657Mar 05 06:11 PM
Gallagher Daniel Martin JrChief Legal OfficerMar 02Option Exercise0.007,811012,093Mar 05 06:09 PM
BRESCH HEATHER MChief Executive OfficerMar 02Option Exercise0.0022,2120384,223Mar 05 06:06 PM
Vollebregt Sjoerd SDirectorMar 02Option Exercise0.004,02808,258Mar 05 06:33 PM
VANDERVEEN RANDALL LDirectorMar 02Option Exercise0.004,028045,845Mar 05 06:30 PM
van der Meer Mohr PaulineDirectorMar 02Option Exercise0.004,56604,566Mar 05 06:27 PM
PARRISH MARK WDirectorMar 02Option Exercise0.004,028041,423Mar 05 06:25 PM
KORMAN HARRYDirectorMar 02Option Exercise0.004,566024,816Mar 05 06:23 PM
HIGGINS MELINA EDirectorMar 02Option Exercise0.004,028013,120Mar 05 06:22 PM
DIMICK NEIL FDirectorMar 02Option Exercise0.004,028048,645Mar 05 06:21 PM
Lyons Dillon JoEllenDirectorMar 02Option Exercise0.004,028013,667Mar 05 06:20 PM
Cindrich Robert JDirectorMar 02Option Exercise0.004,028023,107Mar 05 06:16 PM
Malik RajivPresidentFeb 19Option Exercise0.0014,5890584,940Feb 21 06:01 PM
Parks Kenneth ScottChief Financial OfficerFeb 19Option Exercise0.004,837011,550Feb 21 06:00 PM
BRESCH HEATHER MChief Executive OfficerFeb 19Option Exercise0.0025,2870751,359Feb 21 06:00 PM
Campbell PaulSee RemarksFeb 19Option Exercise0.001,216023,157Feb 21 06:00 PM
Mauro AnthonyChief Commercial OfficerFeb 19Option Exercise0.007,9430160,520Feb 21 06:00 PM
Malik RajivPresidentFeb 17Option Exercise0.0022,0240579,185Feb 20 06:02 PM
Parks Kenneth ScottChief Financial OfficerFeb 17Option Exercise0.002,14907,733Feb 20 06:00 PM
Campbell PaulSee RemarksFeb 17Option Exercise0.00540022,207Feb 20 06:00 PM
Mauro AnthonyChief Commercial OfficerFeb 17Option Exercise0.009,0150156,699Feb 20 05:00 PM
BRESCH HEATHER MChief Executive OfficerFeb 17Option Exercise0.0037,0940742,601Feb 20 05:01 PM
CAMERON WENDYDirectorJun 29Option Exercise0.004,028076,735Jul 03 04:35 PM